Human Follitropin delta
- Generic Name
- Human Follitropin delta
- Indication
用于接受辅助生殖技术周期治疗(如：体外受精等)的女性中进行控制性卵巢刺激，以获得多个卵泡发育，帮助需要促排卵治疗的患者实现可预测的卵巢反应。
Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT06561958
- Locations
- 🇹🇭
Ferring Investigational Site, Bangkok, Thailand
Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT05499052
- Locations
- 🇨🇭
Ferring Investigational Site, Basel, Switzerland
A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation
Phase 3
Completed
- Conditions
- Infertility
- Interventions
- Other: GONAL-F (Follitropin Alfa)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 302
- Registration Number
- NCT05263388
- Locations
- 🇬🇧
Ferring Investigational Site, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath